Cereno Scientific launches initiative for data quality control of CardioMEMS HF System providing an opportunity to report early efficacy data in Q4
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced an initiative to control the data quality produced from the cutting-edge technology CardioMEMS HF System (Abbott Inc.) used to daily monitor blood pressure in the pulmonary circulation and other cardio-pulmonary hemodynamics during the Phase II study of CS1. The remarkable patient case study presented in June triggered the initiative for data quality control of CardioMEMS measurements to ensure optimal data quality for CS1 in this study.